№ files_lp_3_process_9_16254
File format: docx
Character count: 7903
File size: 40 KB
A prospective study assessing the level of knowledge among patients with hepatic cirrhosis regarding their disease, identifying gaps in understanding, and proposing tailored educational programs to improve therapeutic adherence and disease management.
Year:
2021
Region / City:
Tangier, Morocco
Topic:
Hepatic Cirrhosis, Patient Knowledge, Therapeutic Education
Document Type:
Research Study
Author(s):
R. ARDIF, W. BOUKAMZA, I. ELFADLI, A. AKJAY, H. OUAYA, H. MEYIZ, I. MELLOUKI
Target Audience:
Medical professionals, researchers, healthcare providers
Study Period:
2020-2021
Date of Approval:
Not specified
Date of Changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2011
Region / City:
Queensland
Subject:
Legal Procedure
Document Type:
Court Application
Authority / Institution:
Supreme Court of Queensland
Author:
(Not specified)
Target Audience:
Legal professionals, parties involved in representative proceedings
Effective Period:
(Not specified)
Approval Date:
(Not specified)
Amendment Date:
(Not specified)
Year:
2024
Region / City:
District 20, District 5, District 9, Area 6, Area 8, Area 19
Topic:
Alcoholics Anonymous, General Service, Conferences, Area Assemblies
Document Type:
Meeting Minutes
Organization:
Alcoholics Anonymous
Author:
Not specified
Target Audience:
Members of Alcoholics Anonymous, GSRs, Area Officers
Period of Validity:
January 2024 - March 2024
Approval Date:
January 2024
Date of Changes:
February 2024
Year:
2024
Region / City:
Dunedin, New Zealand
Theme:
Waitangi Day, Treaty of Waitangi, New Zealand history
Document Type:
Speech
Organization:
Flagstaff Community Church
Author:
Reverend Brendon McRae
Target Audience:
Congregation members, New Zealand citizens, those interested in Treaty of Waitangi discussions
Date of Approval:
4 February 2024
Date of Changes:
Not specified
Context:
A message reflecting on the significance of Waitangi Day and the relationship between Māori and Pākehā in New Zealand, highlighting scripture, faith, and cultural discussions surrounding Te Tiriti o Waitangi.
Year:
2013
Region / City:
India
Topic:
Conversion of LLP to Company
Document Type:
Procedure
Organization / Institution:
Ministry of Corporate Affairs
Author:
Not specified
Target Audience:
LLP Partners, Proposed Directors
Effective Period:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2024
Note:
Region / City
Topic:
Clinical Trials, Gastroenterology, Cirrhosis
Document Type:
Scientific Article
Author:
Liu J, MacNaughtan J, Kerbert A, et al.
Target Audience:
Medical Researchers, Healthcare Professionals
Year:
2024
Region / City:
Nanfang Hospital
Theme:
Hepatology, Cancer Diagnosis
Document Type:
Scientific Methodology
Institution:
Nanfang Hospital
Author:
Unspecified
Target Audience:
Medical Professionals, Researchers
Period of Action:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Context:
This document presents the diagnostic criteria for cirrhosis and hepatocellular carcinoma, including imaging techniques and laboratory results, based on a multi-center study with radiomics and deep learning features for prediction models.
Authors:
Petar Avramovski; Julijana Petrovska; Maja Avramovska
Affiliations:
St. Clement of Ohrid University – Bitola; Clinical Hospital – Bitola
Country:
North Macedonia
City:
Bitola
Medical Field:
Gastroenterology; Hepatology; Diagnostic Ultrasound
Type of Document:
Scientific research abstract
Study Design:
Observational clinical study
Study Population:
325 patients with non-alcoholic fatty liver disease (NAFLD)
Average Age of Participants:
54.2±8.5 years
Institutions Involved:
Department of Ultrasonography; Department of Gastroenterohepatology; Department of Gynecology and Obstetrics, Clinical Hospital – Bitola
Methods:
B-mode ultrasound imaging, echogenicity analysis software, laboratory tests for platelets, ALT and AST, calculation of FIB-4 score
Diagnostic Indicators Studied:
Hepatorenal Index (HRI); Fibrosis-4 (FIB-4) score
Conditions Examined:
Non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; liver fibrosis; cirrhosis
Patient Group Classification:
Mild NAFLD; moderate NAFLD; severe NAFLD; significant fibrosis (≥F2); advanced fibrosis (≥F3); cirrhosis (F4)
Keywords:
hepatorenal index; FIB-4 score; NAFLD; liver fibrosis; cirrhosis; ultrasound diagnostics
Year:
2013–2021
Region / City:
United States, Canada
Subject:
Cirrhosis and liver disease coding
Document type:
Supplementary table / Research data
Institution:
University of Pennsylvania health system; Parkland Hospital; Outpatient hepatology clinic in Toronto
Authors:
Nehra, Goldberg, Niu, Philip, Hagstrom
Target population:
Patients with cirrhosis or liver disease
Validation status:
Mixed validated and non-validated algorithms
Coding system:
ICD-9-CM, ICD-10-CM
Conditions covered:
Cirrhosis, decompensated cirrhosis, hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic fatty liver disease, hepatocellular carcinoma, liver transplant
Data extraction method:
Algorithm-based diagnosis code identification
Clinical relevance:
Identification and classification of liver disease conditions for research and clinical coding purposes
Reference:
Peer-reviewed studies and expert consensus statements
Supplementary notes:
ICD-10-CM codes derived using GEM mapping when not directly validated
Year:
Not specified
Region / City:
Not specified
Topic:
Medical Research / Hepatology
Document Type:
Research Table
Author:
Not specified
Target Audience:
Medical professionals, researchers
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
Not specified
Topic:
Microbiome diversity in liver disease
Document Type:
Scientific figure description
Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers and clinicians in hepatology and microbiology
Study Population:
Patients with infected decompensated cirrhosis
Analysis Methods:
Phylogenetic diversity (PD) whole tree, principal component analysis
Outcome:
Comparison of survival and mortality during admission and follow-up
Year:
Not specified
Medical condition:
Cirrhosis
Study focus:
2-year all-cause mortality
Methodology:
Multivariate Cox proportional hazards analysis
Clinical variables analyzed:
Hepatic encephalopathy (HE); neutrophil-to-lymphocyte ratio (NLR); ascites; alcohol use; MELD 3.0 score >18
Population:
Hospitalized patients with cirrhosis
Outcome measure:
Hazard ratio (HR) with 95% confidence interval (CI) and p value
Clinical scoring system:
MELD 3.0 (Model for End-Stage Liver Disease)
Document type:
Supplementary statistical table
Statistical indicators:
Hazard ratio (HR); confidence interval (CI); p value
Year:
1993-2022
Region / Country:
Multicenter / International
Topic:
Infectious complications in cirrhosis
Document Type:
Supplementary table
Source / Journal:
Various peer-reviewed medical journals
Authors:
Multiple, see references
Study Type:
Observational studies
Sample Size:
Variable across studies
Assessment Criteria:
Sample frame, sampling method, data coverage, identification methods, measurement reliability, statistical analysis, response rate, risk of bias
Target Population:
Patients with liver cirrhosis
Key Outcomes:
Infection prevalence, risk factors, mortality, multidrug resistance
Endorsement / Approval:
Peer-reviewed publication
Data Collection Period:
1993–2022
Language:
English
Quality Assessment:
Low to moderate risk of bias
Year:
2023
Journal:
World Journal of Gastroenterology
Manuscript Number:
82876
Type:
Mini Review
Authors:
Giuseppe Marrone, Amato Serra, Luca Miele, Marco Biolato, Antonio Liguori, Antonio Grieco, Antonio Gasbarrini
Affiliation:
Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Corresponding Author:
Giuseppe Marrone, MD, PhD
Received Date:
December 28, 2022
Revised Date:
January 24, 2023
Accepted Date:
April 20, 2023
Published Online:
May 21, 2023
Keywords:
Branched-chain amino acids, Hepatic encephalopathy, Sarcopenia, Liver cirrhosis
Focus:
Review of clinical evidence for BCAAs supplementation in cirrhosis-related complications
Patient Population:
Individuals with liver cirrhosis
Complications Discussed:
Hepatic encephalopathy, Sarcopenia
Treatment Approaches:
BCAAs supplementation, non-absorbable disaccharides, antibiotics, supportive therapies
Evidence Type:
Literature review of clinical studies and guidelines
Year:
2019
Region / city:
London
Theme:
Chronic Hepatic Encephalopathy, Shared Care, Prescribing Guidelines
Document type:
Guideline
Organization / institution:
St George’s University Hospitals NHS Foundation Trust, NHS Croydon, NHS Kingston, NHS Merton, NHS Richmond, NHS Sutton, NHS Wandsworth
Author:
Dr. Sarah Clark, Dr. Tony Brzezicki, Dr. Vinodh Kumar, et al.
Target audience:
General Practitioners, Hospital Consultants, Healthcare Professionals
Effective period:
From December 30, 2019
Approval date:
January 23, 2020
Review date:
December 30, 2021
Date of changes:
July 12, 2019, September 26, 2019, October 4, 2019
Year:
2010-2024
Region / city:
Asia-Pacific
Subject:
Hepatology
Document Type:
Clinical Practice Guidelines
Organization / Institution:
Asian Pacific Association for the Study of the Liver (APASL)
Author:
APASL
Target Audience:
Healthcare professionals
Period of validity:
2010-2024
Date of approval:
2010
Date of revisions:
2024
Context:
Collection of clinical practice guidelines and consensus statements issued by the Asian Pacific Association for the Study of the Liver on various hepatological conditions, including hepatocellular carcinoma, hepatitis B and C, liver transplantation, and metabolic diseases.
Authors:
Yanxi Mu; Weixiong Zhu; Wentao Ma; Yu Cheng; Bo Ren; Yusheng Cheng; Wence Zhou
Affiliations:
The Second Clinical Medical College, Lanzhou University, Lanzhou, China; Department of General Surgery, Biotherapy, Lanzhou University Second Hospital, Lanzhou, China; Gansu Province Precision Diagnosis and Treatment Engineering Research Center of Hepatobiliary Pancreatic Diseases; Gansu Province Key Laboratory of Environmental Oncology, Lanzhou, China
Corresponding authors:
Yusheng Cheng; Wence Zhou
Running head:
MSCs and Exosome Therapy in HIRI
Type of document:
Supplementary information to a systematic review and meta-analysis
Subject:
Mesenchymal stem cells and exosomes in hepatic ischaemia reperfusion injury
Study design:
Systematic review and meta-analysis of rodent studies
Databases searched:
PubMed; Web of Science; Embase; Cochrane Library; ClinicalTrials.gov
Outcomes assessed:
ALT; AST; Suzuki’s score; necrotic area ratio; serum TNF-α; cleaved caspase-3
Experimental model:
70% hepatic ischaemia reperfusion injury with 60 or 90 minutes of ischemia in rodents
Content elements:
Funnel plots; forest plots; search strategies; summary of mechanisms and outcome data
Year:
2023
Region / City:
Rochester, Minnesota, USA; Padova, Italy
Topic:
Hepatic steatosis, glucagon, amino acid metabolism
Document Type:
Supplementary data for research article
Institution:
Mayo Clinic; University of Padova
Authors:
Hannah E. Christie, Sneha Mohan, Aoife M. Egan, Federica Boscolo, Chiara Dalla Man, Scott M. Thompson, Michael Jundt, Chad J. Fleming, James C. Andrews, Kent R. Bailey, Michael D. Jensen, K. Sree Nair, Adrian Vella
Target Audience:
Biomedical researchers, clinicians
Clinical Trial Registration:
NCT05500586
Conflict of Interest:
Adrian Vella consulted for Boehringer-Ingelheim, Neurotronics, and Rezolute; other authors declared no conflicts
Data Type:
Experimental measurements, statistical analyses, figures, and tables
Methods:
Splanchnic glucose and amino acid metabolism assays, linear regression analysis, clamp studies
Study Population:
Lean and obese subjects with varying hepatic Proton Density Fat Fraction (PDFF)
Supplementary Figures:
1–8
Supplementary Tables:
1–3
Correspondence:
Adrian Vella, Mayo Clinic, Rochester, MN, USA, [email protected]
Year:
2016
Region / city:
Australia
Topic:
Pharmaceutical utilisation / hepatic encephalopathy
Document type:
Analytical report
Organization / institution:
Drug Utilisation Sub-Committee (DUSC), Department of Human Services (DHS)
Author:
DUSC
Target audience:
Healthcare policymakers, clinicians
Period covered:
December 2013 – March 2016
Date of listing:
1 December 2013
Drug:
Rifaximin
Indication:
Prevention of hepatic encephalopathy recurrence
Dosage:
550 mg twice daily
Treatment requirements:
Combination with lactulose if tolerated; prior episodes of HE required
Regulatory authority:
Therapeutic Goods Administration (TGA)
PBS restriction:
Specialist treatment only; telephone authority approval required
Study type:
Retrospective utilisation analysis
Key findings:
Patient numbers higher than predicted; prescriptions per patient lower than estimated; expenditure aligned with second-year projections
Year:
2021
Region / City:
Kyiv, Ukraine
Field:
Medical Research
Document Type:
Clinical Study
Organization:
Bogomolets National Medical University, Taras Shevchenko National University of Kyiv
Authors:
Elina Manzhalii, Valentyna Moyseyenko, Vitalii Kondratiuk, Nataliia Molochek, Tetyana Falalyeyeva, Nazarii Kobyliak
Target Audience:
Medical professionals, researchers in gastroenterology and hepatology
Duration:
January 2017 - March 2020
Approval Date:
February 22, 2022
Date of Last Revision:
August 1, 2021
Year:
2023
Region / City:
Tai’an, China
Topic:
Protein succinylation, hepatic metabolism, liver diseases
Document Type:
Research Article
Institution:
Shandong Agricultural University
Author:
Shuang Liu, Rui Li, Yawen Sun, Hai Lin, Haifang Li
Target Audience:
Researchers, healthcare professionals
Period of Action:
N/A
Approval Date:
N/A
Date of Changes:
N/A